Electronic Theses and Dissertations

Date of Award


Document Type


Degree Name

M.S. in Pharmaceutical Science


Pharmaceutics and Drug Delivery

First Advisor

Chalet Tan

Second Advisor

Walter Chambliss

Third Advisor

Seongbong Jo

Relational Format



Small molecules functioning as negative regulators of MDM2 have been considered as promising anti-cancer agents. A series of novel anthraquinone (AQ) analogues upregulate p53, a well-known tumor suppressor, by inactivating its antagonist protein MDM2. The novel AQ compounds synthesized through the modifications on the rhein scaffold were reported to have successfully arrested tumor growth. To have a better understanding of their underlying metabolism in vivo, pharmacokinetic (PK) studies were performed for the AQ compounds. A selective, accurate and reproducible assay methodology for PK study was set up for each AQ compound. The stabilities of AQ compounds were then evaluated in terms of different pharmacokinetic properties. All AQ compounds were found unstable in plasma or eliminated from the systemic circulation in mice rapidly possibly due to their structural instability or rapid hepatic metabolism. The correlation between in-vitro stability and in-vivo metabolism can give a good guide for future PK studies.

Included in

Pharmacology Commons



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.